Recurrent Respiratory Papillomatosis Foundation

On May 19 The RRP Task Force, headed by Dr. Craig Derkay held their Spring 2016 meeting in Chicago. Representing the RRP Foundation at this meeting, is long time RRP patient and advocate, Kim McClellan.

Highlights of the meeting compiled by Kim McClellan:

RRP Task Force Meeting Minutes
Hyatt Regency Hotel
Chicago, IL
May 19, 2016

Members Present: Craig Derkay, Ben Anthony, Harlan Muntz, Simon Best, Elissa Meites, Kim McClellan (RRPF), Seth Pransky, Jeffery Simons, Libby Smith, Matt Brigger, David Tunkel, Marc Thorne, Chris Hartnick, Henry Milczak, Shazia Peer, Yang Xiao, Terri Giordano, Adam Klein, Scott Schraff, Farrel Buchinsky, Stephen Conley, Fred Dikkers, Pamela Mudd, Bill Stern-RRPF (via Skype)

Dr. Derkay opened the meeting with information regarding a few RRP focused lectures during COSM. RRP lecture on HPV immunology treatment/polarization, Zeitels on minimally invasive airway procedures as they related to RRP, a lecture on Difficult Airways, as well as a lecture (ASP) on the Efficacy of High Dose Avastin as it relates to RRP.
➢ June 2016, the RRPF was made aware of a presentation at COSM by Dr. Zur, of CHOP, regarding Avastin, used in intravenous infusions, in a pediatric case of pulmonary RRP/tracheal RRP with success.

Upcoming RRP events and RRP Grants:
a. International HPV Eurogen meeting in Salzburg, Austria
b. Core grant, $19,976 (approved by ASPP board):
Prosser, Georgia Regents University, “Characterizing Xenograt Models of Recurrent Respiratory Papillomatosis”
c. ASPO Survey approved: Goodstein, Nemours, “HPV Vaccination Attitudes and Current Practices”

Vaccine Update:

o Gardasil 9: approved 2015, will be replacing the prior Gardasil vaccine. G9 appears to be better tolerated than previous Gardasil. You do not need to administer G9 if the patient has already had the prior vaccine. Can switch to 9 if already in a Gardasil series. CDC current guidelines on age is: Female-9-26, Male-9-21.
Immunogenicity and Safety of a 9-valent HPV vaccine
• —Van Damme P, Pediatrics, 2015;136;e28-e39
• —3066 women 16-26 given 9-valent vaccine
• —>99% seroconverted for each vaccine HPV type
• —Responses in girls and boys were non-inferior to those of these young women
• —Persistence of response demonstrated 2.5-3yrs after dose 3
• —Generally well-tolerated with mild injection site AE’s
• —Conclude: Data support guidelines adopted by ACIP
• —Comment: Encouraging safety and immunogenicity data

o VGX-3100:
John Hopkins, Simon Best, ASPO grant award. VGX-3100 includes plasmids targeting the E6 and E7 proteins of HPV types 16 and 18. Intramuscular injection of the plasmid DNA immunotherapy is followed by electroporation using the CELLECTRA® delivery device. In a phase II trial, VGX-3100 induced regression of precancerous cervical disease and cleared HPV infection with robust T cell responses. http://www.cancerresearch.org/news-publications/our-blog/september-2015/new-study-hpv-vaccine-holds-promise-in-treating-cervical-cancer
• How this relates to RRP: There are DNA vaccines that target the HPV E6 and E7 proteins which are also the key proteins for HPV6/11. If they are successful in producing a therapeutic response with the HPV 16/18, extension to HPV 6/11 should be straightforward. With HPV 16/18 being more oncogenic and related to cervical cancer, it represents a much larger market than the RRP community, hence the initial focus on those HPV types.

o ADXS11:
Mt. Sinai; ADXS11-001 immunotherapy using a live Listeria monocytogenes bioengineered to secrete a HPV-16-E7 fusion protein targeting HPV transformed cells. Currently focusing on Tonsil and Tongue Base HPV. (How it relates to RRP, see above.)

Cidofovir:
Mention was made on how European colleagues could access:
Samir Parikh
CEO
Nexcape Pharmaceuticals Ltd.
15 Martinfield Business Centre
Welwyn Garden City
AL7 1HG
United Kingdom
Phone: +44 20 3667 3070 / Fax: +44- 20 3163 0707

Pegasys:
Pegasys is a new alpha-interferon which seems to be better tolerated. For assistance in administering to pediatric RRP patients, contact Kathleen Schwarz, MD, Pediatric Hepatologist at Hopkins, 410-955-8769

Celebrex:
Dr. Bettie Steinberg will be presenting the findings of this study in Salzburg. General result is that it worked no better than the placebo. Several comments were made to the quality of this study and how it was formed and implemented. The word “ideal” when referencing the study design was used.

Misc:
A. Genetics Study: Dr. Buchinsky reported on interim results regarding 611 patients. Still analyzing HLA data. Preliminary data on his study showed age at DX greatest predictor of clinical course. Has tissue and HPV sub-typing on 230 children and 60 adults. (To be noted, there were at least two dissentions on his results based on prior patient data in those present and their cohorts. This result also goes against RRPF data showing type as the strongest indicator of disease process.)

B. “Three Peaks”, Dr. Dikkus. Dr. Dikkus then described his study recognizing “Three Peaks”, a study using all white Europeans. He showed three peaks for JORRP. Seven years of age, thirty-four years of age and sixty-two to sixty-four years of age. Mentioned this correlated with a Costa Rican study of 20K oral HPV cases. Seemed to be some disagreement into whether this actually matched what others saw in their group. Dikkus study is published in “Clinical Otolaryngology.”

C. Emory Tissue Bank: Adam Klein’s tissue bank is up and running collecting blood, saliva and tissue (mostly in adults with RRP, but open to all). Goal will be to coordinate collection of relevant demographics with CDC study in children with RRP. Currently with 49 adult patients in the tissue bank. Additional pediatric tissue banks created at San Diego, Mass Eye and Ear as well as CDC.
• San Diego: Growing papilloma for in vitro for drug testing
• Boston: Growing RRP in epithelial cells and coordinating with Dr. Schlegel in DC to try and create an immortalized cell line.

D. Dr. Pransky, researcher, is doing in-vitro sampling/testing with possible therapeutic drugs on tissues grown in the lab from patients. Currently phase two and will be requesting some funding from the RRPF.

How the tissue banks relate to RRP: having an extensive collection of RRP patient’s tumor tissues should help researchers with new drug testing. They can do full genomic sequencing on the tumors to see if they can find genetic alterations that might respond to specific treatments.

CDC Study:
A representative from the CDC was in attendance (Elissa Meites, Atlanta). Currently there are 18 pediatric centers in the U.S. enrolled with 93 patients in the study. JORRP cases only. No mention of this including any patients that were JORRP and are now adults. Centers must have IEB approval and sub-award agreements to participate. Started study in 2015 and looking to type specific DNA/Antibodies. Boston Children’s and University of Tennessee latest to come on board.
EVMS 2
Children’s Hospital Cincinnati 16
University of Kansas 3
Children’s National Research Institute 5
University Alabama 8
Indiana 2
Emory 4
Johns Hopkins 23
Lurie Childrens 14
Nationwide Childrens 4
University Maryland 3
University of Kansas 3
University of Minnesota 1
Children’s Hospital of Philadelphia 2
Utah Childrens 3

Additional centers interested in participating should contact Dr. Derkay and Laura Stone, RN for assistance in getting started. craig.derkay@chkd.org stonelj@evms.edu

Additional Gardasil 9:

MUSC-Twenty patients with retroactive Gardisil vaccine showed varied response rates. Some increased intervals between procedures by three months, this was not controlled. Based upon this “study”, males showed greatest response.
http://www.ncbi.nlm.nih.gov/pubmed/25619468

Dr. Dikkers of the Netherlands, introduced us to a recently available study he was part of regarding Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis. http://www.ncbi.nlm.nih.gov/pubmed/27188508 This has no clinical response data, only measured antibody response.

Should Gardasil (or the upcoming 9-valent vaccine) be initiated earlier than at age 9 to our RRP patients? The group agreed that this would be appropriate. Data gathering at individual sites where this is pursued is encouraged for use in the future in a potential retrospective study. Suggested that this may be delivered at the time of surgical interventions to encourage third party payers to cover the cost.

Ideas for RRP Task Force Research Initiatives:

• HPV sub typing: Matt Brigger: Systematic review completed. Difficult to control for age in the meta-analysis. Type 11 appears to be more aggressive in terms of need for tracheotomy, adjuvant therapy, distal spread. Heated debate among the Task Force regarding which factor (early age of onset vs. HPV type) is most predictive of aggressive course in children. (RRPF data indicates HPV type as indicator, but for a given HPV type early age onset may also be a factor.)

• A decision was made to pursue a publication based upon the systematic review including a Task Force recommendation to sub-type all pediatric RRP patients.

• After the RRP Task Force meeting, Dr. Derkay met with Dr. Jack Krouse, Editor of OTO-HNS (white journal) and secured a commitment to publish an Invited Commentary on this topic to be authored by Drs. Brigger, Dikkers, Buchinsky, Hartnick and Derkay.

New Business:

A please for Open Access of RRP research data was made-specifics of how this may be accomplished in the future to come.

Please be generous and contribute to the ASPO RRP Research Fund to continue funding of pilot projects. To date we have raised only $67K towards our goal of $100K. ASPO Board will only issue awards every other year until we can reach our goal. You may contribute to the ASPO “Sustaining the Future” campaign and designate your contribution to the Micah RRP Research Fund. Checks should be sent to:

ASPO RRP Research Fund
c/o Bruce Maddern, ASPO Treasurer
10475 Centurion Pkwy N
Suite 302
Jacksonville, FL 32256
drmaddern@gmail.com

(this is a merged document of advocate minutes and Task Force minutes)

Craig Derkay, MD, FACS, FAAP
Professor and Vice-Chairman
Department of Otolaryngology Head Neck Surgery
Eastern Virginia Medical School
Children’s Hospital of the King’s Daughters
Norfolk, VA 23507
craig.derkay@chkd.org (o)757-668-9853 (c) 757-439-5752

Kim McClellan, RRPF Advocate and Task Force Meeting Representative
Chicago, IL
themcclellanfamily@comcast.net

Dear RRP Community,

It is with deep sadness and sorrow that I am letting you know that Jenn
Woo, President of the RRPF, has passed away from complications
associated with pulmonary RRP and lung cancer. Over the last few years
despite having to battle this most challenging form of RRP, she
completed her medical degree at Georgetown and became a practicing
physician. More details will be forthcoming.

She touched the lives of so many of us and will be sorely missed.

With much sympathy to her family and friends,
Bill

In late December 2014, the RRP Foundation awarded a $5000 grant to the Georgetown University Center for Cell Reprogramming.  A research team headed by Dr. Hang Yuan has been investigating the use of “reprogrammed cells” to target therapies for individual RRP patients.  An initial progress report detailing this approach was publish in the New England Journal of Medicine in September of 2012.  the abstract and article can be found at:

http://www.nejm.org/doi/full/10.1056/NEJMoa1203055#t=abstract

On May 30,  2014, Johns Hopkins sponsored a CME course/meeting on RRP –

“Updates in Recurrent Respiratory Papilloma: Clinical and Research Perspectives”

There were a number of interesting talks and discussions. In addition to the RRP Foundation President, Jenn Woo (who was one of the invited speakers), about 12 RRP family members attended the meeting.

A detailed summary can be found at:
http://rrpf.org/meetings/Hopkins2014/HopkinsRRPcoursePatientsFamiliesPerspective.pdf

RRPF poster presentation:
http://rrpf.org/meetings/Hopkins2014/RRP_Hopkins2014_Poster_b.pdf

It is with much sadness that we report the passing of Phil Sensenbach, who died this past November. Phil was a long time member of our RRP patient network. He was diagnosed at the age of 18 months and battled RRP throughout his life. Phil sought solace in religion and spirituality, support from friends and groups. RRP shaped his life and how he lived it. He very much hoped for a cure, but was consumed by the challenges of RRP, which eventually lead to his death at the young age of 45. He spent much of his life in Middletown, NJ, not far from where Marlene and I live. We communicated with Phil a number of times by phone but regret never having the opportunity to have met him in person. He is survived by his son Justin, parents Ronald and Frances, and grandfather Lewis.

Our thoughts and prayers are with Phil’s family.